Screener
Stryker SYK Orthopaedics — D&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Stryker in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Stryker’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 11:10 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000310764-26-000031
| Segment Results | Three Months / 2026 | Three Months / 2025 |
|---|---|---|
| Orthopaedics | 880 | 925 |
| Segment selling, general and administrative expenses | $1,810 | $1,784 |
| MedSurg and Neurotechnology | $55 | $48 |
| Orthopaedics | 119 | 107 |
| Segment depreciation and amortization | $174 | $155 |
| Corporate and Other | $43 | $39 |
| Amortization of intangible assets | 180 | 167 |
| Total depreciation and amortization | $397 | $361 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Stryker's orthopaedics — D&A?
- Stryker (SYK) reported orthopaedics — D&A of $119M in Q1 2026.
- How has Stryker's orthopaedics — D&A changed year-over-year?
- Stryker's orthopaedics — D&A increased by 11.2% year-over-year, from $107M to $119M.
- What is the long-term trend for Stryker's orthopaedics — D&A?
- Over 3 years (2022 to 2025), Stryker's orthopaedics — D&A has grown at a 7.3% compound annual growth rate (CAGR), from $350M to $432M.
- What does orthopaedics — D&A mean?
- This represents the non-cash allocation of the cost of tangible and intangible assets used by the Orthopaedics segment over their useful lives. It reflects the wear and tear of manufacturing equipment and the amortization of acquired intellectual property or patents. Tracking this provides insight into the capital intensity of the segment's operations.
Ask your AI about Stryker's orthopaedics — d&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude